Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome Efficacy of Pentosan Polysulfate Treatment
Main Article Content
Keywords
bladder pain syndrome, Efficacy, Interstitial cystitis, Pentosan Polysulfate, treatment
Abstract
Objectives: Pentosan Polysulfate (PPS) is the only oral treatment for interstitial cystitis (IC)-bladder pain syndrome (BPS) approved by the World Health Organization. Self-evaluation scales can provide more objective results on pre- and post-treatment satisfaction. The aim of this study was to investigate the effect of pentosan polysulfate treatment on symptoms in IC-BPS patients.
Methods: This study included 37 adult male and female patients with IC-BPS who reported pain, urinary urgency, polyurea, and nocturia without urinary tract infection for a minimum of six months prior to the study and were taking 300 mg/day oral pentosan polysulfate. Pre- and post-treatment symptoms, Interstitial Cystitis Symptom Index (ICSI) Scores, quality of life (QoL) scores (1‒4), and satisfaction conditions were examined.
Results: Following the application of inclusion and exclusion criteria, mean age of 37 suitable patients was 46.0±11.9 years and 27% (10 individuals) of the patients were male. Pre-treatment, ICSI scores, and measures of satisfaction degree and QoL increased significantly after the treatment (p<0.001). Adverse reaction was detected in two patients (5.4%) among the patients treated with pentosan polysulfate.
Conclusions: Oral pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome treatment could achieve recovery in symptoms, increase Interstitial Cystitis Symptom Index score and improve quality of life and patient satisfaction.
Metrics
References
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. ; Standardisation Sub-Committee of the International Continence Society.The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003 Jan;61(1):3749. https://doi.org/10.1016/S0090-4295(02)02243-4 PMID:12559262
3. Sand PK, Kaufman DM, Evans RJ, Zhang HF, Alan Fisher DL, Nickel JC. Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008;24(8):2259-64. Epub 20080625. https://doi.org/10.1185/03007990802240727.PMID: 18582395.
4. Rosenberg MT, Hazzard M. Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol. 2005 Dec;174(6):2231-4. https://doi.org/10.1097/01.ju.0000181203.82693.95 PMID:16280776
5. Marcu I, Campian EC, Tu FF. Interstitial Cystitis/Bladder Pain Syndrome. Semin Reprod Med. 2018;36(2):123-35. Epub 20181219.https://doi.org/10.1055/s-0038-1676089. . PMID: 30566978.
6. Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545-53. Epub 20150123. https://doi.org/10.1016/j.juro.2015.01.086 PMID: 25623737.
7. Nickel JC, Herschorn S, Whitmore KE, Forrest JB, Hu P, Friedman AJ, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857-62. Epub 20140920.https://doi.org/10.1016/j.juro.2014.09.036.. PMID: 25245489.
8. O'Leary MP, Sant GR, Fowler FJ, Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58-63. https://doi.org/10.1016/S0090-4295(99)80333-1.PMID: 9146003.
9. Arda E, Cakiroglu B, Tas T, Ekici S, Uyanik BS: Use of the UPOINT Classification in Turkish Chronic Prostatitis or Chronic Pelvic Pain Syndrome Patients. Urology. 2016, 97:227-23. https://doi.org/10.1016/j.urology.2016.07.023 PMID:27476153
10. Giusto LL, Zahner PM, Shoskes DA. An evaluation of the pharmacotherapy for interstitial cystitis. Expert Opin Pharmacother. 2018;19(10):1097-108. Epub 20180704. https://doi.org/10.1080/14656566.2018.1491968. PMID: 29972328.
11. Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35-48. Epub 20090831. https://doi.org/10.1016/j.eururo.2009.08.020.PMID: 19733958.
12. Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993 Sep;150(3):845-8. https://doi.org/10.1016/S0022-5347(17)35629-X PMID:7688432
13. van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019;35(9):1495-503. Epub 20190319. https://doi.org/10.1080/03007995.2019.1586401.PMID: 30849922.
14. Holm-Bentzen M, Jacobsen F, Nerstrøm B, Lose G, Kristensen JK, Pedersen RH, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987 Sep;138(3):503-7. https://doi.org/10.1016/S0022-5347(17)43241-1 PMID:2442415
15. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al ; Interstitial Cystitis Clinical Trials Group.. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810-5. https://doi.org/10.1097/01.ju.0000083020.06212.3d PMID:12913705
16. Hwang P, Auclair B, Beechinor D, Diment M, Einarson TR. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology. 1997 Jul;50(1):39-43. https://doi.org/10.1016/S0090-4295(97)00110-6 PMID:9218016
17. Wyndaele JJJ, Riedl C, Taneja R, Lovasz S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535-44. Epub 20181228. https://doi.org/10.1002/nau.23900.PMID: 30592544.
18. Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol. 1987 Sep;138(3):508-12. https://doi.org/10.1016/S0022-5347(17)43242-3 PMID:2442416
19. Clemens JQ, Calhoun EA, Litwin MS, McNaughton-Collins M, Kusek JW, Crowley EM, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009;74(5):983-7, quiz 7 e1-3. Epub 20091002. dhttps://doi.org/10.1016/j.urology.2009.06.078. PMID: 19800663; PubMed Central PMCID: PMCPMC2783956.
20. van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005 Nov;174(5):1837-40. https://doi.org/10.1097/01.ju.0000176741.10094.e0 PMID:16217303
21. Guidelines EA 2022. Available from: https://uroweb.org/guidelines/chronic-pelvic-pain
22. Anderson VR, Perry CM. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs. 2006;66(6):821-35. https://doi.org/10.2165/00003495-200666060-00006 PMID:16706553
23. Tseng CS, Chang SJ, Meng E, Chang HC, Lee YJ. The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial. J Formos Med Assoc. 2020;119(8):1314-9. Epub 20191205. https://doi.org/10.1016/j.jfma.2019.11.007. PMID: 31813658.
24. Wang D, Velaga SB, Grondin C, Au A, Nittala M, Chhablani J, et al. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening. Am J Ophthalmol. 2021;227:125-38. Epub 20210227.https://doi.org/10.1016/j.ajo.2021.02.025. PMID: 33651989.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with the Bladder agree to the following terms:
- Authors retain copyright and grant the Bladder right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
